NGM Biopharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NGM research report →
About the company
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH).
- CEO
- David J. Woodhouse
- IPO
- 2019
- Employees
- 138
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $128.53M
- P/E
- -0.89
- P/S
- 29.10
- P/B
- 0.85
- EV/EBITDA
- -0.48
- Div Yield
- 0.00%
- Gross Margin
- 49.72%
- Op Margin
- -3317.79%
- Net Margin
- -3223.34%
- ROE
- -69.76%
- ROIC
- -98.49%
- Revenue
- $4.42M · -92.02%
- Net Income
- $-142,375,000 · 10.50%
- EPS
- $-1.73 · 13.07%
- Op Income
- $-146,547,000
- FCF YoY
- 8.78%
- 52W High
- $4.69
- 52W Low
- $0.60
- 50D MA
- $1.55
- 200D MA
- $1.49
- Beta
- 1.26
- Avg Volume
- 1.07M
Get TickerSpark's AI analysis on NGM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 5, 24 | TCG Opportunity III GP, LLC | other | 1,000 |
| Apr 5, 24 | TCG Opportunity III GP, LLC | sell | 44,000 |
| Apr 5, 24 | COLUMN GROUP GP, LP | other | 1,000 |
| Apr 5, 24 | COLUMN GROUP GP, LP | sell | 44,000 |
| Apr 5, 24 | COLUMN GROUP L P | other | 1,000 |
| Apr 5, 24 | COLUMN GROUP L P | sell | 44,000 |
| Apr 5, 24 | GOEDDEL DAVID V | other | 1,000 |
| Apr 5, 24 | GOEDDEL DAVID V | sell | 100,000 |
| Apr 5, 24 | GOEDDEL DAVID V | sell | 24,000 |
| Apr 5, 24 | GOEDDEL DAVID V | sell | 19,619 |
Our NGM coverage
Recent articles, reports, and earnings notes.
No research on NGM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NGM report →Similar companies
Peers in the same neighborhood.